Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $20.00 | Neutral | Analyst |
| 11/6/2024 | $22.00 → $19.00 | Buy → Neutral | BofA Securities |
| 10/11/2024 | $24.00 | Overweight | KeyBanc Capital Markets |
| 8/12/2024 | $22.00 | Buy | BofA Securities |
| 8/12/2024 | $18.00 | Buy | Loop Capital |
| 8/12/2024 | $24.00 | Overweight | Stephens |
| 8/12/2024 | $21.00 | Buy | Citigroup |
| 8/12/2024 | $23.00 | Outperform | RBC Capital Mkts |
Ardent Health Partners, Inc. (NYSE:ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that its board of directors voted to change the Company's name to Ardent Health, Inc., effective June 3, 2025. The updated name aligns the Company's legal name with its practice of referring to the organization as "Ardent Health" in its communications, ensuring a clear and consistent brand identity. The name change will have no impact on Ardent Health's trading symbol on the New York Stock Exchange, its CUSIP number, nor the rights of its stockholders. Ardent Health anticipates that its common stock will begin
Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Chris Schoeplein as chief development officer. In this new role, Schoeplein will lead development efforts across Ardent's existing markets and support the organization's expansion into new regions. He will be responsible for driving growth across inpatient and outpatient care settings through acquisitions, partnerships and joint ventures. Additionally, he will guide due diligence, market intelligence and integration planning to advance Ardent's long-term growth strategy. "We are excited to welcome Chris to Ardent at a pivotal time in our gr
Ardent Health Partners, Inc. (NYSE:ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced results for the quarter ended March 31, 2025. First Quarter 2025 Operating and Financial Summary All comparisons are versus the same prior year period. See the footnotes to the Operating Statistics table of this press release for definitions of the metrics below and a full list of key operating metrics. Total Revenue $1.50 billion 4.0% growth Y/Y Net Income Attributable to Ardent Health $41 million Adjusted EBITDA(1) $98 million 2.5% growth Y/Y Adjusted EBITDAR(1) $139 million
Analyst resumed coverage of Ardent Health Partners with a rating of Neutral and set a new price target of $20.00
BofA Securities downgraded Ardent Health Partners from Buy to Neutral and set a new price target of $19.00 from $22.00 previously
KeyBanc Capital Markets initiated coverage of Ardent Health Partners with a rating of Overweight and set a new price target of $24.00
4 - Ardent Health Partners, Inc. (0001756655) (Issuer)
4 - Ardent Health Partners, Inc. (0001756655) (Issuer)
3 - Ardent Health Partners, Inc. (0001756655) (Issuer)
4 - Ardent Health Partners, Inc. (0001756655) (Issuer)
8-K - Ardent Health Partners, Inc. (0001756655) (Filer)
10-Q - Ardent Health Partners, Inc. (0001756655) (Filer)
8-K - Ardent Health Partners, Inc. (0001756655) (Filer)
Ardent Health Partners, Inc. (NYSE:ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced results for the quarter ended March 31, 2025. First Quarter 2025 Operating and Financial Summary All comparisons are versus the same prior year period. See the footnotes to the Operating Statistics table of this press release for definitions of the metrics below and a full list of key operating metrics. Total Revenue $1.50 billion 4.0% growth Y/Y Net Income Attributable to Ardent Health $41 million Adjusted EBITDA(1) $98 million 2.5% growth Y/Y Adjusted EBITDAR(1) $139 million
Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its first quarter 2025 results after the market closes on Tuesday, May 6, 2025. A conference call will be held the following day, Wednesday, May 7, 2025, at 10:00 a.m. ET to review the Company's financial results, discuss recent events and conduct a question-and-answer session. A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent's website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time
Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its fourth quarter and full year 2024 results after the market closes on Wednesday, February 26, 2025. A conference call will be held the following day, Thursday, February 27, 2025, at 9:00 a.m. ET to review the Company's financial results, discuss recent events and conduct a question-and-answer session. A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent's website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior
Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Chris Schoeplein as chief development officer. In this new role, Schoeplein will lead development efforts across Ardent's existing markets and support the organization's expansion into new regions. He will be responsible for driving growth across inpatient and outpatient care settings through acquisitions, partnerships and joint ventures. Additionally, he will guide due diligence, market intelligence and integration planning to advance Ardent's long-term growth strategy. "We are excited to welcome Chris to Ardent at a pivotal time in our gr
Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Robert A. DeMichiei to its board of directors. A seasoned leader with over 30 years of experience in financial strategy, healthcare operations, and board governance, Mr. DeMichiei served as executive vice president and chief financial officer at the University of Pittsburgh Medical Center (UPMC) from 2004 to 2020. During his tenure, he played a pivotal role in driving UPMC's financial growth and led numerous strategic initiatives, including mergers and acquisitions, supply chain management, and revenue cycle improvements. Prior to joining U
Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Dave Caspers as chief operating officer. In this new role, Caspers will oversee operations across Ardent Health, which includes 30 hospitals and 280 sites of care in six states. He will be responsible for executing on strategic growth initiatives and driving operational excellence at an enterprise level. Caspers will also lead efforts to further optimize and scale the company's consumer-centric operating model across new and existing markets. "We are pleased to welcome Dave to Ardent," said Ardent Health President and CEO Marty Bonick. "His
SC 13G - Ardent Health Partners, Inc. (0001756655) (Subject)
SC 13G - Ardent Health Partners, Inc. (0001756655) (Subject)
SC 13G - Ardent Health Partners, Inc. (0001756655) (Subject)